InSphero ranked #2 Startup of the Year in Switzerland

Share Article

InSphero AG, experts in three-dimensional microtissue technology, is proud to announce that the company has been ranked number 2 startup in the TOP 100 Swiss Startups 2012 list and recognized for its global success and customer base of top pharma companies.

...business veterans, investors and startup experts recognize the global awareness that InSphero has generated for 3D cell culture and its sustainably growing business.

Around 100 experts from the Swiss business startup scene have ranked InSphero number 2 startup (all categories) in Switzerland and, again, as in 2011, number 1 startup in the biotech space. The jury recognized the global success of InSphero's 3D microtissue technology for more predictive compound testing and the fact that InSphero currently counts 7 of the top 10 global pharmaceutical and cosmetics companies as customers.

Dr Jan Lichtenberg, Chief Executive Officer and Co-founder of InSphero, says: “At InSphero we are very proud of the accomplishment and appreciate the recognition accorded to the company and its dedicated employees. This is a great success for us, given the strengths of other startup companies in Switzerland. At the same time this high ranking is a clear indication that business veterans, investors and startup experts recognize the global awareness that InSphero has generated for 3D cell culture and its sustainably growing business.”

To find out more about InSphero visit http://www.insphero.com

To read the official media coverage (in German only) visit http://www.startup.ch

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, currently counts 7 of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy (e.g. in oncology) and toxicology, including long-term and inflammation-mediated toxicity. A broad portfolio of tumor and liver microtissues is available from a number of cell sources, with additional toxicology models in the pipeline. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards and is also certified to the ISO 9001:2008 standard for its Quality Management System.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Manuela Vujevic
InSphero AG
+41-44-5150490
Email >
Follow us on
Visit website